Rhythm Pharmaceuticals develops and commercializes therapies for rare neuroendocrine diseases that cause severe obesity and uncontrolled hunger. Its lead product, IMCIVREE (setmelanotide), is an MC4R pathway agonist approved for genetic obesity syndromes such as Bardet-Biedl syndrome and certain POMC/LEPR deficiencies, and has expanded into acquired hypothalamic obesity. The company focuses on precision medicine for small, highly defined patient populations rather than mass-market weight-loss drugs.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q1 2025 | 32.7 | — | -50.8 | — |
| Q2 2025 | 48.5 | — | -48 | — |
| Q3 2025 | 51.3 | — | -54.3 | — |
| Q4 2025 | 57.3 | — | -48.8 | — |
| Q1 2026 | 60.1 | 83.8% | -56.7 | — |
| Q2 2026 | 71.3 | 46.9% | -50.4 | — |
All markets — KeepWinning global stock screener
Other companies on Nasdaq: Crocs, Inc. (CROX), Allegro MicroSystems, Inc. (ALGM), Ligand Pharmaceuticals Incorporated (LGND), Caesars Entertainment, Inc. (CZR), Hancock Whitney Corporation (HWC), TeraWulf Inc. (WULF)